Molecular epidemiology study of Mycobacterium tuberculosis and its susceptibility to anti-tuberculosis drugs in Indonesia by Vivi Lisdawati et al.
RESEARCH ARTICLE Open Access
Molecular epidemiology study of Mycobacterium
tuberculosis and its susceptibility to anti-tuberculosis
drugs in Indonesia
Vivi Lisdawati1*, Nelly Puspandari2, Lutfah Rif’ati2, Triyani Soekarno2, Melatiwati M2, Syamsidar K2, Lies Ratnasari3,
Nur Izzatun3 and Ida Parwati3
Abstract
Background: Genotyping of Mycobacterium tuberculosis helps to understand the molecular epidemiology
of tuberculosis and to address evolutionary questions about the disease spread. Certain genotypes also have
implications for the spread of infection and treatment. Indonesia is a very diverse country with a population with
multiple ethnicities and cultures and a history of many trade and tourism routes. This study describes the first
attempt to map the molecular epidemiology of TB in the Indonesian archipelago.
Method: From 2008 to 2011, 404 clinical specimens from sputum-smear (SS+) TB patients, age ≥15 years, were
collected from 16 TB referral primary health centers (PHC) in 16 provincial capitals in Indonesia. Susceptibility testing
to first line drugs was conducted for 262 samples using the agar proportion method as per WHO guidelines.
Spoligotyping was done on all samples.
Results: Ninety-three of the 404 samples (23 %) were from the Beijing family, making it the predominant family in
the country. However, the geographic distribution of the family varied by region with 86/294 (29.3 %) in the western
region, 6/72 (8.3 %) in the central region, and 2/72 (2.8 %) in the eastern region (p < 0.001). The predominant genotype
in the central and eastern regions was from the East-African-Indian (EAI) family, comprising 15.3 % (11/72), and 26.3 %
(10/38) of the isolates, respectively. Drug susceptibility to first-line anti-TB drugs was tested in 262 isolates.
162 (61.8 %) isolates were susceptible to all TB drugs, 70 (26.7 %) were mono-resistant 16 (6.1 %) were poly-resistant, and
14 (5.4 %) were multi-drug resistant (MDR). The proportion of Beijing family isolates in the susceptible, mono-resistant,
poly-resistant, and MDR groups was 33/162 (20.4 %), 28/70 (40.0 %), 6/16 (37.5 %), and 3/14 (21.4 %), respectively.
Overall, resistance of the Beijing family isolates to any of the first line TB drugs was significantly higher than non-Beijing
families [37/71 (52.1 %) vs. 63/191 (33.0 %) (p-value = 0.003)].
Conclusion: The distribution of Mycobacterium tuberculosis genotypes in Indonesia showed high genetic diversity and
tended to vary by geographic regions. Drug susceptibility testing confirmed that the Beijing family of M.tb in Indonesia
exhibited greater resistance to first line anti-TB drugs than did other families.
Background
Tuberculosis (TB) remains a major global health prob-
lem and ranks as the second leading cause of death from
an infectious disease worldwide. There were 9 million
new TB cases and 1.5 million TB related deaths in 2013.
Among these deaths, it was estimated that more than
200,000 were due to MDR-TB, a high proportion of the
480,000 incident cases of MDR-TB [1]. A serious prob-
lem has been the emergence of extensively-drug resist-
ance TB (XDR-TB) comprising 9 % of the MDR cases.
The treatment of MDR- and XDR-TB is substantially
more costly and difficult to treat, with higher rates of
treatment failure and mortality, as compared to drug-
susceptible tuberculosis [2, 3].
Indonesia is considered a high-burden country for TB,
ranked fifth in TB incidence (460,000 new TB patients
each year) worldwide [1]. An Indonesian National Basic
Health Survey in 2010 reported 289 cases/100,000
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population [4]. According to the Indonesian TB pre-
valence survey in 2004, differences in TB prevalence
among different regions was observed. For example, 82
cases/100,000 population were reported in the Java-Bali
region, compared with 343 cases/100,000 population in
Eastern Indonesia and 217 cases/100,000 population in
the Sumatra-Kalimantan region [5]. The differences in
the incidences is likely multifactorial and may include
such factors such as income level, hygiene, education
and availability of health care facilities [2, 4, 6].
In addition to the high prevalence of TB cases, drug-
resistant DR-TB is also an important problem in
Indonesia. WHO estimated 1.9 % of new TB cases and
12 % of previously treated TB cases in Indonesia have
MDR-TB [1]. Several studies reveal that MDR-TB occurs
more frequently in patients with a previous history of
pulmonary TB treatment, particularly those with inad-
equate treatments (including monotherapy, insufficient
duration of therapy or inconsistency of adherence), and
in patients with co-morbidities, including human im-
munodeficiency virus (HIV) infection or diabetes melli-
tus (DM) [3, 4]. There are risk factors for the occurrence
of mutations in the specific genes of the bacteria that
may lead to drug-resistance. The prevalence of MDR-TB
in Indonesia also varies geographically. According to the
TB resistance survey conducted between 2004 and 2007,
the prevalence of MDR-TB in Central Java, Makassar
and Papua was 1.9 %, 4.1 % and 2.0 %, respectively [2].
Therefore, it is important to understand both the geo-
graphic distribution of bacterial genotypes as well as the
susceptibility of individuals within different regions
according to the possibility of genetic susceptibility
mutations [7].
Although MDR-TB is emerging throughout Indonesia,
there is only one study of nearly 900 patients that evalu-
ates drug resistance and M. tb genotypes. This study did
not find drug resistance associated with certain geno-
types. However, it did find that the Beijing genotype,
found more frequently in West Java (Bandung) than in
West Timor (Kupang), was associated with treatment
failure [8, 9].
Here we describe the initial mapping of 404M. tb
bacterial genotypes using spoligotyping, the sensitivity
of M. tb isolates to first line anti-TB drugs, and the asso-
ciation between the genotypes and drug sensitivity,
which will complement the previous publication of this
study [10].
Methods
A cross-sectional study was conducted in 16 TB referral
primary health centers (PHC) that had the ability to per-
form microscopic sputum examination. The study was
conducted in 16 provincial capitals in Indonesia, including
five provincial capitals in Sumatra (Bandar Lampung,
Palembang, Padang, Medan and Pekan Baru), four in Java
(Serang, Jakarta, Bandung and Surabaya) two in Kalimantan
(Banjarmasin and Pontianak), two in Sulawesi (Makassar
and Menado) and three in Eastern Indonesia (Mataram,
Ambon and Sorong) between 2008 and 2010. Ethical clear-
ance was obtained from the Ethics Review Committee of
NIHRD of Indonesia. Laboratory procedures were per-
formed according to the algorithm in Fig. 1.
Subjects and samples
Individual sputum samples were collected from 437 sub-
jects who met the inclusion criteria: i) age ≥ 15 years, ii)
newly diagnosed TB or in treatment less than two months,
iii) sputum smear positive, and iv) willingness to sign in-
formed consent. Subjects whose sputa were not available
were not included in the study. Sputum samples collected
by PHC technicians from suspected TB patients included
a spot sputum on day 1 and an early morning sputum and
a spot sputum on day 2. All patients were trained by the
PHC technicians how to produce sputum as per national
TB guidelines to ensure that all sputum from different
PHC were comparable. All sputum were sent to and proc-
essed by the National Institute of Health Research and
Development (NIHRD) in Jakarta. NIHRD’s laboratory
technicians then chose one of the three sputa based on
the quality of the sputum (macroscopically thick, pus-like,
sometimes bloody, and microscopically having more
leukocytes than epithelial cells). Sputum samples from 13




Sputum specimens were decontaminated using
MycoPrep™, a solution containing sodium hydroxide
and N-acetyl-L-cysteine, in Falcon tubes, following
sputum decontamination guidelines [11], in Biosafety
cabinet class II type A2 using Personal Protective
Equipment (PPE) for Biosafety Laboratory Level-3
(BSL-3). This suspension was divided into two
aliquots and stored in an incubator at 37 °C. for
further process . One aliquot was prepared for
DNA extraction (for genotyping and spoligotyping)
and the second aliquot was prepared for culture
(for genotyping and susceptibility testing).
Spoligotyping and genotyping test were performed
first on sputum to shorten the time to obtain results.
B. DNA Extraction, Liquid Culture Media BACTEC
MGIT-960 and Solid Culture Media Lowenstein
Jensen (LJ)
The first aliquot above was used for genotyping.
M. tb DNA was isolated according to the method of
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DNA extraction, as described in the kit manual
(®Qiagen) using the manufacturers protocol. The
extracted DNA was eluted from QIAspin columns
in a final volume of 200 μL AE buffer and stored
at −70°C until used for genotyping. When the
genotype pattern could not be obtained from DNA
isolated from the first aliquot, due to the limitation
of direct sputum processing, genotyping was then
attempted from the second aliquot.
The second aliquot was divided into two. The first
part was added to the Falcon tubes that contained
BACTEC™ MGIT™ Oleic acid, Albumin, Dextrose,
Catalase (OADC) growth supplement and MGIT
PANTA antimicrobic mixture (®BD. Location exact
details of kit). M. tb liquid MGIT Bactec culture was
performed as per the kit manual prepared by the
manufacturer. The second part was added to the
Lowenstein-Jensen (L-J)media for solid culture as
per WHO guidelines [12]. All preparation was done
in biosafety cabinet Class II Type A2 using PPE for
BSL-3. When the Bactec MGIT-960 media culture
showed M. tb growth at 2 – 4 weeks, some isolates
were used for genotyping. When the L-J media
culture showed M. tb growth at 2 – 8 weeks, the
isolates were used for first line anti-TB susceptibility
test and some isolates were also used for genotyping.
C. Spoligotyping
Testing was performed on DNA isolates from the
first aliquot and from some cultures according to
the manufacturing procedure for spoligotyping for
M.tb’s DNA [13], using primer DRA: 5'-GCT TTT
GGG TCT GAC GAC-3 'labeled with biotin at the
5' end and primer DRB: 5'-CCG AGA GGG GAC












































Fig. 1 The scheme of the laboratory procedures conducted to sample sputa from 16 TB refferal health center in 16 provincial capitals
in Indonesia
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H37Rv and M.bovis BCG as positive control, to
avoid false negative or false positive results. To
minimize false negative and false positive results,
we separated the PCR mix chamber with sample
preparation room and implemented appropriate
techniques during mini-blotter use to avoid air-bubles.
Amplification of DNA was conducted using a
thermocycler (AB System). PCR products were then
hybridized using the mini-blotter MN45 equipment as
per instructions from the manufacturer. Hybridization
results were compared with the data base patterns on
Spoligotipe Data Base (SPOLDB4/SITVIT) and the
dendrogram was constructed using software
BioNumerics v6.0.
D. First line anti-TB Drug Susceptibility Test
Susceptibility testing was conducted in accordance
with the agar proportion method by WHO [12].
First line drugs used in this test were Streptomycin,
Isoniazid, Rifampicin and Ethambutol (SIRE)
with susceptibility cutoff concentrations [4; 0.2; 40;
2 (μg/ml)]. Results were interpreted by observing the
presence or absence of M. tb bacteria on 28 day
cultured samples compared to negative control.
M. tb strains were considered resistant when isolates
showed at least 1 % resistance by counting the
bacteria growth as per the WHO formula and were
considered sensitive when <1 % isolates showed
resistance. When day 28 results were resistant, the
reading was not repeated and strains were
considered resistant. However, when day 28 reading
resulted in sensitive results, samples were re-read
on day 42. Readings on day 42 were considered
definitive readings.
Results
A total of 437 subjects were consented, with the ma-
jority from the western region (302/69.1 %), followed by
the eastern (76/17.4 %) and central regions (59/13.5 %).
The western, central and eastern regions consisted of 11,
2 and 3 PHCs, respectively. Each PHC contributed 20 to
30 subjects. The subjects were 15–74 years of age, with
a median of 32 years. The ratio between males and females
was 1.8:1. This ratio was found in 12 PHC, except in
Makassar where it was equal, and in Serang, Banjarmasin
and Sorong where females were slightly more than males.
Details of the regions and cities where the PHCs are
located are listed in Table 1.
Thirteen of the 437 sputa from these patients were con-
taminated during specimen processing, and were excluded
from further analysis. Spoligotyping and culture growth
(in liquid MGIT Bactec 960 media and solid L-J media)
were performed on 424 sputa. During spoligotyping 381
sputa were hybridized and 43 did not hybridize. Culture
on liquid and solid media resulted in growth of 305 and
262M. tb samples, respectively. Spoligotyping repeated
using the isolates from these culture, resulting in 23
additional hybridizations of 43 subjects who had not hy-
bridized to spoligotyping performed from the direct sputa
specimens. In total, the genotypes of M. tb from 404 sub-
ject could be characterized, both from sputa and culture
in liquid and solid media (Fig. 1).
Based on spoligotyping results, molecular epidemio-
logy data demonstrated genotype diversity of M. tb in
Indonesia [Table 2], where 404 patterns of M. tb strains
match with 149 patterns on the spoligotype database
(SPOLDB4/SITVIT). Overall our study found that the
largest number of M. tb isolates in Indonesia belonged
to the Beijing family (93/404, 23.0 %), followed by East
African Indian/EAI-type (Family F) (83/404, 20.5 %) and
Latin American-Mediterranean/LAM-type (Family D)
(50/404, 12.4 %). Fifty-seven patterns of M. tb were not
in the SPOLDB4 database and were designated as or-
phan type (14.1 %). The Beijing family was the most pre-
dominant (86/29.3 %) genotype in the western region,
followed by the EA family (62/21.1 %) genotype, LAM
family (10.9 %) genotype and orphan (10.5 %) group. In
contrast, Beijing family was only found in 6M. tb (8.3 %)
isolates in the central region and in 1M. tb (2.6 %)
isolate in eastern region. The difference in prevalence of
the Beijing family in the western region compared to the
other regions was significant (p < 0.01). The EA (11/15.3 %)
and LAM genotypes (10/13.9 %) was predominant in the
central region. The EA was also the most predominant in
the eastern region (10/26.3 %), followed by LAM and T
genotypes (each 8/21.1 %) (Table 2).
Drug susceptibility results from 262 culture positive
samples were matched with their respective spoligotyp-
ing results. Details of drug susceptibility results to first
line drugs, MDR and poly-resistant, non MDR in each
town, region and across all sites are detailed in Table 1.
The proportion of M. tb isolates that were susceptible to
all first line TB drugs in Indonesia was 61.8 % and this
was not different between the regions (western: 62 %,
central: 57.1 %, eastern: 66.7 %). There were some cities
where the prevalence of drug sensitive TB was higher such
as Surabaya (81.3 %), Mataram (77.8 %) and Banjarmasin
(72.7 %). In contrast, in Lampung, Bandung, and Pakan
Baru, the prevalence of drug sensitive TB was ≤ 50 %.
The proportion of MDR across all sites was 5.3 %. The
majority of this was concentrated in the western and cen-
tral regions (6 % and 5.3 %). Interestingly, no MDR strains
were found in 33M. tb isolates from the eastern part of
Indonesia. In western Indonesia, MDR M. tb isolates were
identified, in order of frequency, from Lampung (5),
Jakarta (3), Pontianak (2), Pekan Baru (1), Bandung (1),
and in central Indonesia from Makassar (1) and Manado
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Table 1 The list of the cities, number of screened subjects and results of spoligotyping and resistance testing
Cities Screened Spoligotyping L-J cultured Resistance Susceptible (%)
(%) Str INH Rif Eth MDR Poly-drug
INH+ RIF Resistance
Western Region 302 284 (186/98) 201 17 20 3 12 12 13 124 (62)
Padang 29 25 (17/8) 18 2 2 0 0 0 2 12 (66.7)
Pekan Baru 30 29 (23/6) 14 2 1 0 1 1 2 7 (50)
Palembang 30 30 (21/9) 16 0 2 0 1 0 2 11 (68.8)
Lampung 28 26 (18/8) 20 2 2 1 2 5 0 8 (40)
Medan 20 19 (14/5) 16 2 2 2 1 0 0 9 (56.3)
Serang 29 29 (14/15) 24 2 2 0 1 0 1 18 (75)
DKI Jakarta 28 28 (19/9) 16 2 0 0 0 3 1 10 (62.5)
Bandung 26 24 (16/8) 22 1 4 0 3 1 4 9 (40.9)
Surabaya 30 30 (17/13) 16 2 1 0 0 0 0 13 (81.3)
Banjarmasin 25 17 (8/9) 22 2 2 0 2 0 0 16 (72.7)
Pontianak 27 27 (19/8) 17 0 2 0 1 2 1 11 (64.7)
Central Region 59 59 (36/23) 28 2 6 0 0 2 2 16 (57.1)
Makassar 30 30 (15/15) 18 2 3 0 0 1 2 10 (55.6)
Manado 29 29 (21/8) 10 0 3 0 0 1 0 6 (60)
Eastern Region 76 61 (36/25) 33 7 1 1 1 0 1 22 (66.7)
Mataram 28 13 (12/1) 9 1 1 0 0 0 0 7 (77.8)
Ambon 28 28 (15/13) 15 2 0 1 1 0 1 10 (66.7)
Sorong 20 20 (9/11) 9 4 0 0 0 0 0 5 (55.6)
Total 437 404 (258/146) 262 26 27 4 13 14 16 162 (61.8)
Table 2 Details of M. tb spoligotyping results divided into each region in Indonesia
GenotypeMtb Western region freq (%) Central region freq (%) Eastern region freq (%) Total
Beijing strain (fam. I) 86 (29.3) 6 (8.3) 1(2.6) 93
H genotype (fam. A) 23 (7.8) 9 (12.5) 2 (5.3) 34
LAM genotype (fam. D) 32 (10.9) 10 (13.9) 8 (21.1) 50
EA genotype (fam. F) 62 (21.1) 11 (15.3) 10 (26.3) 83
T genotype (fam. C) 20 (6.8) 4 (5.6) 8 (21.1) 32
U genotype (fam. G and H) 21 (6.8) 9 (12.5) 2 (5.3) 32
MANU1 genotype (fam. others) 6 (2) - - 6
MANU2 genotype (fam. others) 3 (1) 2 (2.8) - 5
X1 genotype(fam. B) 6 (2) - - 6
CAS genotype (fam. others) 3 (1) - - 3
PINI genotype (fam. others) - - 1 (2.6) 1
Africanum genotype (fam. others) - 1 (1.4) - 1
Orphan 31 (10.5) 20 (27.8) 6 (15.8) 57
H37Rv 1 (0.3) - - 1
TOTAL 294 72 38 404
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(1). Of note, although almost 60 % (13/22) of M. tb iso-
lates from Bandung had some resistance to first line TB
drugs, only one was MDR. Resistance to single drugs was
most frequent (36.3 %), followed by poly-drug, non-MDR
(18.2 %) and MDR (4.5 %).
Analysis of M. tb susceptibility in the Beijing family and
non-Beijing family groups is described in Table 3. The
Beijing family demonstrated the highest mono-resistance
[28/70(40.0 %)], followed by poly-resistant, drug sensitive
TB, and MDR groups [6/16(37.5 %)], [33/162(20.4 %)] and
[3/14(21.4 %)], respectively.
The resistance amongst the Beijing family to any first
line TB drug was significantly higher than in the non-
Beijing families (52.9 %% vs 32.8 %, p < 0.01). This higher
resistance was largely due to the mono-resistant group
(40 % vs 21.9 %, p < 0.01), and with some contribution
from the poly-resistant group (8.6 % vs 5.2 %, p = 0.31).
This was not seen when comparison was made between
MDR strains in each group (4.3 % vs 5.7 %, p = 0.64).
Further analysis of the resistance to each first line drug,
individually or in combination with other drugs, revealed
that the prevalence of resistance to INH was higher in
the Beijing family (28.6 %) compared to (18.2 %) in non-
Beijing family but this was not statistically significant.
Similarly, the prevalence of resistance to rifampicin in
Beijing family (8.6 %) was not significantly higher than
non-Beijing family (6.8 %). Resistance to ethambutol was
significantly higher in the Beijing family compared to
non-Beijing groups (17.1 % vs 5.2 % p < 0.01). In con-
trast, resistance to streptomycin in the Beijing group was
not significantly lower than in the non-Beijing family
(11.4 % vs 14.6 %).
Discussion
This study adds to the data available in Indonesia with
respect to M. tb starins and drug resistance in the vari-
ous regions of the country. The majority of subjects in
this study are between 15–54 years, reflecting the age
group with high mobility as a routine activity in this age
group as known. The proportion of males in our study
was higher than female which could suggest that TB
prevalence was higher in men than in women. This is
consistent with the results of National Indonesian Basic
Health Research in 2010, [4] which showed that the
prevalence of TB in Indonesia is higher in men. An epi-
demiological study in India in 1986–2002 also found
gender bias in TB patients [14]. Research to determine
the role of paternal relationship or Y chromosome on
the suseptibility of Mtb, along with research on genetic
influences sensitivity exposed by the host with a particu-
lar type Mtb is underway [15, 16]. Recent study showed
that the specific gene like CYP7A1 gene, which codes
for cholesterol 7a-hydroxylase, an enzyme involved in
cholesterol catabolism, may play a role in susceptibility
to TB in human population [7]. However, given the
strong patrilineal cultural factors in Indonesian society,
where men are considered more important in all aspects,
including in access to medical treatment should be
considered.
This study used spoligotyping to obtain genotyping
data. This method has proven to be an effective and effi-
cient method for the study of genotypes in the popula-
tion because it can be used to construct a dendrogram
structure that describes the circulation of the group
(clade) of M. tb, while also being able to recognize the
existing lines [16, 17]. When compared with other fin-
gerprinting methods such as restriction fragment length
polymorphism (RFLP) with a probe of the sequence
IS6110, spoligotyping has an advantage because this
method has a probe on the membrane which in addition
to distinguishing genotype can simultaneously recognize
strains of M. tb complex, which can not be done by
probes on conventional RFLP method in a single reac-
tion process [8, 9]. Due to limits in the number of pri-
mer used in standard spoligotyping, spoligotyping
generally equipped with Mycobacterial interspersed re-
petitive unit-variable number of tandem repeat (MIRU-
VNTR) typing method that has the ability to provide
more information as it uses more loci [18, 19].
Some samples showed no hybridization on membrane
spoligotyping. Some references indicate that the spoligo-
typing often fails to produce hybridization patterns from
DNA samples derived directly from sputum specimens,
though with appropriate modifications of extraction
Table 3 The susceptibility and resistance of Beijing and
Non-Beijing strain groups to first line anti-TB drugs
Susceptibility/Resistance M.tuberculosis genotype Total
Beijing Non-Beijing
Susceptible 33 129 162
Monoresistance 28 42 70
Streptomycin 6 20 26
INH 11 16 27
Rifampicin 3 1 4
Ethambutol 8 5 13
Multi Drug Resistance (MDR) 3 11 14
Poly-resistance 6 10 16
SI 2 5 7
SR 0 0 0
SE 0 1 1
IE 4 2 6
RE 0 0 0
SIE 0 1 1
SER 0 1 1
Total 70 192 262
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techniques this can be improved [9]. Hybridization fail-
ure may be associated with small numbers of bacteria
present in the sample or the possibility that the bacteria
are dead so that there can be no replication. This is evi-
dent from the results of the evaluation, in which some
samples which did not show a pattern of hybridization
also failed to show growth of colonies on culture media.
This study produced several important findings. The
Beijing family genotype was the predominant M. tb
family in West Indonesian region (Java, Sumatra,
Kalimantan), but was the minority in Eastern Indonesia.
Based on data of M. tb distribution that the W-Beijing
strain family is associated with the migration of ethnic
Chinese [20–22], we speculate that this may be the rea-
son for the dominance of this family in the main trading
cities in Sumatra, Java and Kalimantan. As is well
known, ethnic Chinese first came to Indonesia by sea for
trade and the sampling sites in the western and central
regions were port cities in ancient times. Similar results
have been reported in Parwati, et al. [8].
In contrast, in the region with inaccessible migration
paths, such as the eastern region, the W-Beijing strain
family may not have arrived and other isolates predomin-
ate, such as the East African-Indian (EAI) and Haarlem
(H)-like in Madagascar [23], the type of Latin American-
Mediterranean (LAM) also observed in Turkey [24] or the
typical type of Central Asian Strain (CAS)-like in Pakistan
[25]. Considering the migration theory, this may also illus-
trate that the movement of M. tb strains in east region in
Indonesia also follows the movement of the human popu-
lation of Polynesian and African regions as mentioned
earlier.
Our study also found that the proportion of resistance
to anti-TB drugs within Beijing strains family was signifi-
cantly higher than non-Beijing strains family. This is
consistent with previous research suggesting that a num-
ber of Beijing family have putative mutator genes and
cause changes in DNA repair that will drive the direc-
tion of resistance mutations [26, 27]. Research on Beijing
strains from Germany and Russia showed mutations in a
high proportion of the genes rpoB S531L and embB306. A
study in Hong Kong reports the association between
Beijing strains with phenotypic resistance to INH]. [28, 22]
These mutations indicate any possibility of mutations that
can arise in bacteria gene, especially M. tb gene. Our study
also found no MDR case in the Eastern region. However,
as a study in Northern Malawi showed, for all isolates of
the Beijing still susceptible to anti TB drugs [29], further
study needs to be conducted.
We also found several important M. tb types such as
the H type. Recent molecular studies found this type
should be closely monitored because the 3R gene (DNA
repair, recombination, and replication) reveal a high
tendency to mutate, similar to the Beijing strains, even
though the mechanism is not clear [9]. The prevalence
of MDR-TB was relatively high and the orphan group
was the most common isolate found in the central re-
gion. However, the limitation of spoligotyping as a geno-
typing method has also to be considered when finding
too many orphan M. tb types.
Genotype studies on population using spoligotyping such
as in this study is beneficial to provide the dendogram
structure that could clarify M. tb clade circulation, together
with identifying prevalent strains [30]. Dendrogram data
would be useful for comparing patterns between countries.
This comparison will determine which countries share
similar dendogram patterns. These countries may then
share their experience in TB surveillance programs.
This study has several limitations. First, the difficulty
to maintain the cold chain sample may influence the re-
sults of bacterial culture. In addition, genotyping analysis
was only conducted by spoligotyping without combining
it with another method, such as MIRU – VNTR typing,
which would provide more definitive differentiation of
strains of each family of M. tb because MIRU typing has
more loci to complete the genotyping results. A third limi-
tation of the present study is the relatively small sample
size used for susceptibility testing that may not represent
the true pattern of resistance for the population.
Conclusion
In summary, spoligotyping on 404 sputum specimens from
TB patients highlights the diversity of M. tb genotypes in
Indonesia. The majority of M. tb strains from Java, Sumatra
and Kalimantan was family I (type W-Beijing family strains)
whereas eastern Indonesia was dominated by family F
(type EAI) and family D (type LAM) isolates. Resistance
to anti-TB drugs was more common in W-Beijing family
strains, which, in turn, were more commonly found in
Java. Hence, this finding is an important consideration in
the management of TB in regions with high rates of resist-
ance and suggests that there is a need for the government
to enhance the TB surveillance program in Indonesia.
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